Literature DB >> 8023159

High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.

G M Clore1, J G Omichinski, K Sakaguchi, N Zambrano, H Sakamoto, E Appella, A M Gronenborn.   

Abstract

The three-dimensional structure of the oligomerization domain (residues 319 to 360) of the tumor suppressor p53 has been solved by multidimensional heteronuclear magnetic resonance (NMR) spectroscopy. The domain forms a 20-kilodalton symmetric tetramer with a topology made up from a dimer of dimers. The two primary dimers each comprise two antiparallel helices linked by an antiparallel beta sheet. One beta strand and one helix are contributed from each monomer. The interface between the two dimers forming the tetramer is mediated solely by helix-helix contacts. The overall result is a symmetric, four-helix bundle with adjacent helices oriented antiparallel to each other and with the two antiparallel beta sheets located on opposing faces of the molecule. The tetramer is stabilized not only by hydrophobic interactions within the protein core but also by a number of electrostatic interactions. The implications of the structure of the tetramer for the biological function of p53 are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023159     DOI: 10.1126/science.8023159

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  80 in total

1.  An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes.

Authors:  A L Okorokov; J Milner
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Meanfield approach to the thermodynamics of protein-solvent systems with application to p53.

Authors:  A R Völkel; J Noolandi
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

3.  Protein kinase CK2 interacts with a multi-protein binding domain of p53.

Authors:  C Götz; P Scholtes; A Prowald; N Schuster; W Nastainczyk; M Montenarh
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

4.  Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.

Authors:  M Kanovsky; A Raffo; L Drew; R Rosal; T Do; F K Friedman; P Rubinstein; J Visser; R Robinson; P W Brandt-Rauf; J Michl; R L Fine; M R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

5.  Breaking symmetry in the structure determination of (large) symmetric protein dimers.

Authors:  Vadim Gaponenko; Amanda S Altieri; Jess Li; R Andrew Byrd
Journal:  J Biomol NMR       Date:  2002-10       Impact factor: 2.835

6.  Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain.

Authors:  M McCoy; E S Stavridi; J L Waterman; A M Wieczorek; S J Opella; T D Halazonetis
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

7.  Correcting errors in the BRCA1 warning system.

Authors:  Yanping Liang; William J Dearnaley; Nick A Alden; Maria J Solares; Brian L Gilmore; Kevin J Pridham; A Cameron Varano; Zhi Sheng; Elizabeth Alli; Deborah F Kelly
Journal:  DNA Repair (Amst)       Date:  2018-11-22

8.  Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface.

Authors:  Buyong Ma; Yongping Pan; K Gunasekaran; R Babu Venkataraghavan; Arnold J Levine; Ruth Nussinov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

9.  Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

Authors:  Kasandra J-L Riley; Laura A Cassiday; Akash Kumar; L James Maher
Journal:  RNA       Date:  2006-04       Impact factor: 4.942

10.  Stable production of peptide antigens in transgenic tobacco chloroplasts by fusion to the p53 tetramerisation domain.

Authors:  Susana M Ortigosa; Alicia Fernández-San Millán; Jon Veramendi
Journal:  Transgenic Res       Date:  2009-12-02       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.